Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-03-18
1999-10-12
Naff, David M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424450, 435 911, 435 914, 4351721, 4353201, 536 231, A01N 4336, A61K 9127, C12N 1500, C07H 2102
Patent
active
059655429
ABSTRACT:
Methods of forming cationic liposome
ucleic acid complexes in which the complexes have a mean diameter of about 200 to about 300 nm are provided. The complexes are formed by combining a first solution of preformed cationic unilamellar liposomes with a mean diameter of from 100 to 150 nm, with a second solution of nucleic acid. Each of the solutions are equilibrated prior to mixing to temperatures of from 0.degree. C. to about 12.degree. C., preferably about 2.degree. C. to about 7.degree. C. The preformed cationic liposomes are typically prepared from an unsaturated cationic lipid, for example DODAC, DOTAP, DOTMA, DODAP, DMRIE, DORI, DOSPA and combinations thereof, and a neutral lipid, for example DOPE or cholesterol. The combination of the first and second solutions is typically carried out by gentle mixing over ice for a period of time of from about 10 to about 60 minutes.
REFERENCES:
patent: 4407948 (1983-10-01), Goodman et al.
patent: 5008050 (1991-04-01), Cullis et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5785992 (1998-07-01), Michial et al.
Liu, et al., "New cationic lipid formulations for gene transfer," Pharmaceutical Research, 13:12:1856-1860 (1996).
Brigitte Sternberg, "Morphology of cationic liposome/DNA complexes in relation to their chemical composition," J. Liposome Research, 6(3):515-533 (1996).
Stamatatos, et al., "Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes," Biochem., 27(11):3917-25 (May 31, 1988).
Bertling, et al., "Use of liposomes, viral capsids, and nanoparticles as DNA carriers," Biotech. and Applied Biochem., 13:390-405 (1991).
Fred D. Ledley, "Nonviral gene therapy: the promise of genes as pharmaceutical products," Human Gene Therapy, 6:1129-1144 (Sep. 1995).
Mahato, et al., "Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes," J. Pharm. Sci., 84(11):1267-1271 (Nov. 1995).
Gao, et al., "Potentiation of cationic liposome-mediated gene delivery by polycations," Biochem., 35:1027-1036 (1996).
Lee, et al., "Folate-targeted anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer," 271(14):8481-8487 (Apr. 5, 1996).
Hui, et al., "The role of helper lipids in cationic liposome-mediated gene transfer," Biophysical J., 71:590-599 (Aug. 1996).
Sternberg, et al., "New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy," FEBS Letters, 356:361-366 (1994).
Tomlinson, et al., "Controllable gene therapy pharmaceutics of non-viral gene delivery systems," J. Controlled Release, 39:357-372 (1996).
Kabanov, et al., "DNA complexes with polycations for the delivery of genetic material into cells," Bioconjugate Chem., 6:7-20 (1995).
Xu, et al., "Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection," Biochem., 35:5616-5623 (1996).
Ahkong Quet Fah
Bally Marcel B.
Hope Michael J.
Reimer Dorothy L.
Wasan Ellen K.
Inex Pharmaceuticals Corp.
Naff David M.
LandOfFree
Use of temperature to control the size of cationic liposome/plas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of temperature to control the size of cationic liposome/plas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of temperature to control the size of cationic liposome/plas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-652515